Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.
about
Novel adjunctive therapies for the treatment of tuberculosisModeling tuberculous meningitis in zebrafish using Mycobacterium marinum.Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.Infection dynamics and response to chemotherapy in a rabbit model of tuberculosis using [¹⁸F]2-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.Targeting Batf2 for infectious diseases and cancer.Adjunctive Phosphodiesterase-4 Inhibitor Therapy Improves Antibiotic Response to Pulmonary Tuberculosis in a Rabbit Model.Analysis of glutathione levels in the brain tissue samples from HIV-1-positive individuals and subject with Alzheimer's disease and its implication in the pathophysiology of the disease process.Central nervous system tuberculosis: pathogenesis and clinical aspects.Microglia activation in a pediatric rabbit model of tuberculous meningitisDietary Vitamin D3 Suppresses Pulmonary Immunopathology Associated with Late-Stage Tuberculosis in C3HeB/FeJ Mice.Immunity to TB and targets for immunotherapy.Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Inflammation and tuberculosis: host-directed therapies.Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis.
P2860
Q26829957-08D727BD-C0C4-4F5A-9A2E-20FB5259079DQ34081782-7A00B4BD-C646-4720-8786-5E38DAB43BECQ35166127-88D37B19-D654-4A2D-B2BE-E5D98E990719Q36171653-85D788DF-9543-45E5-873E-532154CB5260Q36413539-E2C87C60-8AE0-47C6-AEA6-70F623581814Q36645097-37E6E57F-9EBE-4FFE-9AA6-F89B0392A079Q37005319-D04B8BCB-C1A4-418F-B3DC-2D3251C39DF0Q37133651-DF4BB703-D530-4DD4-B883-ED9A5E8BB585Q37545421-B3689910-2879-4EEE-AD3B-9B386DE324D8Q37621289-A9B0FB5B-AAAD-431E-9EA2-D02E0EF1A3ABQ37984571-05DC4026-ED39-48F4-88FB-C79A45E54E4EQ38041192-D155CA2F-5FA1-49E4-A2D5-7B9DC170593CQ38074017-CD94BB9D-77EE-4C33-A1ED-CF9421ED8319Q38203352-3FDB9B15-8A90-42D7-8AEA-91F7BC207C10Q39437874-F4034467-8B49-462B-AD6A-FA26F57AA3DA
P2860
Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@ast
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@en
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@nl
type
label
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@ast
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@en
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@nl
prefLabel
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@ast
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@en
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@nl
P2093
P2860
P1476
Use of IMiD3, a thalidomide an ...... mental tuberculous meningitis.
@en
P2093
Bande Mangaliso
David Stirling
George Muller
Liana Tsenova
Victoria H Freedman
P2860
P304
P356
10.1128/AAC.46.6.1887-1895.2002
P407
P50
P577
2002-06-01T00:00:00Z